Logo

Enigma Supplies POC Chlamydia Dx for UK Screening Program

Nov 09, 2007
NEW YORK (GenomeWeb News) — Enigma Diagnostics said today it has developed a DNA assay for the UK healthcare system to screen for Chlamydia trachomatis, the most common treatable sexually transmitted disease in that country.
 
Enigma, based in Porton Down, UK, said its assay, reagents, and instrumentation can detect C. trachomatis DNA from urine and or swab samples “in a matter of minutes.” The test is based on Enigma's fully automated diagnostics platform, which uses real-time PCR to detect bacterial target DNA in samples.
 
Enigma said the Defense Science and Technology Laboratory commissioned the company to create a swift, point-of-care diagnostic for the UK National Chlamydia Screening Program.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.